Amundi Asset Management US’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Amundi Asset Management US’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$347K	Buy	+1,624	New	+$449K	﹤0.01%	1382
2020 Q3	–	Sell	-912	Closed	-$89K	–	1660
2020 Q2	$89K	Buy	+912	New	+$79.8K	﹤0.01%	1442
2019 Q1	–	Sell	-50	Closed	-$13K	–	1698
2018 Q4	$13K	Sell	50 -600	-92%	-$121K	﹤0.01%	1566
2018 Q3	$158K	Sell	650 -123	-16%	-$32.2K	﹤0.01%	1474
2018 Q2	$182K	Buy	+773	New	+$225K	﹤0.01%	1430

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Amundi Asset Management US's EVLO Position: Q1 2021 in Review

Amundi Asset Management US opened a new position in Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2021: 1,624 shares worth $347K. The stake represents ﹤0.01% of the portfolio and ranks #1382 among its holdings. This is a return to the name: Amundi Asset Management US previously reported a position in EVLO as recently as Q2 2020.

Amundi Asset Management US first reported a position in EVLO in Q2 2018 and has held it in 5 quarters since. 62 funds tracked by Wall St. Rank hold EVLO as of Q1 2021.

Amundi Asset Management US held 1,624 shares of Evelo Biosciences, Inc. Common Stock worth $347K as of Q1 2021.
Evelo Biosciences, Inc. Common Stock was a new Amundi Asset Management US position in Q1 2021.
Evelo Biosciences, Inc. Common Stock made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1382 holding.
Amundi Asset Management US first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and has held it in 5 quarters since.
62 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.